Current Gastroenterology Reports

, Volume 9, Issue 6, pp 513–520 | Cite as

Optimizing drug therapy in inflammatory bowel disease



This article reviews current data to optimize the use of both older and newer drugs in inflammatory bowel disease. For patients with severe ulcerative colitis (UC), steroid dosing has been clarified, and a meganalysis of steroid outcomes and toxicities has been reported. In regard to mesalamine, recent information has suggested benefit of a higher dose of pH-dependent release mesalamine for patients with moderate UC. Also, a once-daily formulation with Multi-Matrix System (MMX) technology (Shire Pharmaceuticals, Wayne, PA), has been approved. In regard to cyclosporine, two centers have reported an increased rate of colectomy over a long-duration follow-up of a cyclosporin A course given for UC. Additional information regarding thiopurines has been published, including the use of metabolite testing and duration of therapy for these drugs. Lastly, additional information regarding the optimal method for using anti-tumor necrosis factor therapy continues to accumulate.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Truelove SC, Witts LJ: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955, 2:1041–1048.PubMedCrossRefGoogle Scholar
  2. 2.
    Hanauer S, Sandborn W: Practice Parameters Committee of the American College of Gastroenterology: management of Crohn’s disease in adults. Am J Gastroenterol 2001, 96:635–643.PubMedCrossRefGoogle Scholar
  3. 3.
    Bossa F, Fiorella S, Caruso N, et al.: Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol 2007, 102:601–608.PubMedCrossRefGoogle Scholar
  4. 4.
    Powell-Tuck J, Bown RL, Lennard-Jones JE: A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 1978, 13:833–837.PubMedCrossRefGoogle Scholar
  5. 5.
    Turner D, Walsh CM, Steinhart AH, Griffiths AM: Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007, 5:103–110.PubMedCrossRefGoogle Scholar
  6. 6.
    Scholmerich J: Review article: systemic and topical steroids in inflammatory bowel disease. Aliment Pharmacol Ther 2004, 20(Suppl 4):66–74.PubMedCrossRefGoogle Scholar
  7. 7.
    Faubion WA, Jr, Loftus EV, Jr, Harmsen WS, et al.: The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255–260.PubMedCrossRefGoogle Scholar
  8. 8.
    Lichtenstein GR, Abreu MT, Cohen R, et al.: American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940–987.PubMedCrossRefGoogle Scholar
  9. 9.
    Oren R, Arber R, Odes S, et al.: Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996, 110:1416–1421.PubMedCrossRefGoogle Scholar
  10. 10.
    Buchman AL: Side effects of corticosteroid therapy. J Clin Gastroenterol 2001, 33:289–294.PubMedCrossRefGoogle Scholar
  11. 11.
    Hanauer SB, Stathopoulos G: Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf 1991, 6:192–219.PubMedGoogle Scholar
  12. 12.
    Compston JE, Judd D, Crawley EO, et al.: Osteoporosis in patients with inflammatory bowel disease. Gut 1987, 28:410–415.PubMedCrossRefGoogle Scholar
  13. 13.
    Sakellariou GT, Moschos J, Berberidis C, et al.: Bone density in young males with recently diagnosed inflammatory bowel disease. Joint Bone Spine 2006, 73:725–728.PubMedCrossRefGoogle Scholar
  14. 14.
    Schoon EJ, Bollani S, Mills PR, et al.; Matrix Study Group: Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol 2005, 3:113–121.PubMedCrossRefGoogle Scholar
  15. 15.
    Lichtenstein GR, Sands BE, Pazianas M: Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:797–813.PubMedCrossRefGoogle Scholar
  16. 16.
    Kornbluth A, Hayes M, Feldman S, et al.: Do guidelines matter? Implementation of the ACG and AGA osteoporosis guidelines in inflammatory bowel disease (IBD) patients who meet the guideline’s criteria. Am J Gastroenterol 2006, 101:1546–1550.PubMedCrossRefGoogle Scholar
  17. 17.
    Das KM, Eastwood MA, McManus JP, Sircus W: Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973, 289:491–495.PubMedCrossRefGoogle Scholar
  18. 18.
    Sandborn WJ, Hanauer SB: Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003, 17:29–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Kane S, Huo D, Magnanti K: A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003, 1:170–173.PubMedCrossRefGoogle Scholar
  20. 20.
    Kamm MA, Sandborn WJ, Gassull M, et al.: Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007, 132:66–75, quiz 432–433.PubMedCrossRefGoogle Scholar
  21. 21.
    Lichtenstein GR, Kamm MA, Boddu P, et al.: Effect of once-or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007, 5:95–102.PubMedCrossRefGoogle Scholar
  22. 22.
    Ediger JP, Walker JR, Graff L, et al.: Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007, 102:1417–1426.PubMedCrossRefGoogle Scholar
  23. 23.
    Kruis W, Bar-Meir S, Feher J, et al.: The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003, 1:36–43.PubMedCrossRefGoogle Scholar
  24. 24.
    Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987, 317:1625–1629.PubMedCrossRefGoogle Scholar
  25. 25.
    Hanauer SB, Sandborn WJ, Kornbluth A, et al.: Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005, 100:2478–2485.PubMedCrossRefGoogle Scholar
  26. 26.
    Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841–1845.PubMedCrossRefGoogle Scholar
  27. 27.
    Moskovitz DN, Van Assche G, Maenhout B, et al.: Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006, 4:760–765.PubMedCrossRefGoogle Scholar
  28. 28.
    Actis GC, Fadda M, David E, Sapino A: Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 2007, 7:13.PubMedCrossRefGoogle Scholar
  29. 29.
    McDonald JW, Feagan BG, Jewell D, et al.: Cyclosporine for induction and remission in Crohn’s disease. Cochrane Database Syst Rev 2005, (2):CD000297.Google Scholar
  30. 30.
    Dubinsky MC, Yang H, Hassard PV, et al.: 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904–915.PubMedCrossRefGoogle Scholar
  31. 31.
    Osterman MT, Kundu R, Lichtenstein GR, Lewis JD: Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006, 130:1047–1053.PubMedCrossRefGoogle Scholar
  32. 32.
    Reinshagen M, Schutz E, Armstrong VW, et al.: 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active Crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007, 53:1306–1314.PubMedCrossRefGoogle Scholar
  33. 33.
    Sparrow MP, Hande SA, Friedman S, et al.: Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007, 5:209–214.PubMedCrossRefGoogle Scholar
  34. 34.
    Dubinsky MC, Vasiliauskas EA, Singh H, et al.: 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125:298–303.PubMedCrossRefGoogle Scholar
  35. 35.
    Lémann M, Mary JY, Colombel JF, et al.: A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology 2005, 128:1812–1818.PubMedCrossRefGoogle Scholar
  36. 36.
    Clark M, Colombel JF, Feagan BC, et al.: American Gastroenterological Association Consensus Development Conference on the use of biologics in the treatment of inflammatory bowel disease, June 21–23, 2006. Gastroenterology 2007, 133:312–339.PubMedCrossRefGoogle Scholar
  37. 37.
    Targan SR, Hanauer SB, van Deventer SJ, et al.: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997, 337:1029–1035.PubMedCrossRefGoogle Scholar
  38. 38.
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al.: Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323–333, quiz 591.PubMedCrossRefGoogle Scholar
  39. 39.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002, 359:1541–1549.PubMedCrossRefGoogle Scholar
  40. 40.
    Sands BE, Anderson FH, Berstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004, 350:876–885.PubMedCrossRefGoogle Scholar
  41. 41.
    Colombel JF, Sandborn WJ, Rutgeerts P, et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007, 132:52–65.PubMedCrossRefGoogle Scholar
  42. 42.
    Baert F, Noman M, Vermeire S, et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 2003, 348:601–608.PubMedCrossRefGoogle Scholar
  43. 43.
    Sandborn WJ, Hanauer SB: Infliximab in the treatment of Crohn’s disease: a user’s guide for clinicians. Am J Gastroenterol 2002, 97:2962–2972.PubMedCrossRefGoogle Scholar
  44. 44.
    Mackey AC, Green L, Liang LC, et al.: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:265–267.PubMedCrossRefGoogle Scholar
  45. 45.
    Sandborn WJ, Rutgeerts P, Enns R, et al.: Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829–838.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Henry D. Janowitz Division of GastroenterologyMount Sinai School of MedicineNew YorkUSA

Personalised recommendations